Primary research

Analyses of variant human papillomavirus type-16 E5 proteins for their ability to induce mitogenesis of murine fibroblasts

Rahul Nath, Christine A Mant, Barbara Kell, John Cason* and Jon M Bible

Address: Department of Infectious Diseases, Second Floor New Guy's House, Guy's Hospital, Guy's, King's College and St Thomas' School of Medicine, King's College London, London SE19RT, UK

Email: Rahul Nath - rahul.nath@gstt.nhs.uk; Christine A Mant - Christine.mant@kcl.ac.uk; Barbara Kell - Barbara.Kell@meditechmedia.com; John Cason* - john.cason@kcl.ac.uk; Jon M Bible - jon.bible@kcl.ac.uk

* Corresponding author

Abstract

Background: Human papillomavirus type 16 (HPV-16) E5 protein co-operates with epidermal growth factor to stimulate mitogenesis of murine fibroblasts. Currently, little is known about which viral amino acids are involved in this process. Using sequence variants of HPV-16 E5 we have investigated their effects upon E5 transcription, cell-cycling and cell-growth of murine fibroblasts.

Results: We demonstrate that: (i) introduction of Thr64 into the reference E5 sequence of HPV-16 abrogates mitogenic activity: both were poorly transcribed in NIH-3T3 cells; (ii) substitution of Leu44Val65 or, Thr37Leu44Val65 into the HPV-16 E5 reference backbone resulted in high transcription in NIH-3T3 cells, enhanced cell-cycle progression and high cell-growth; and, (iii) inclusion of Tyr8 into the Leu44Val65 backbone inhibited E5 induced cell-growth and repression of p21 expression, despite high transcription levels.

Conclusion: The effects of HPV-16 E5 variants upon mitosis help to explain why Leu44Val65 HPV-16 E5 variants are most prevalent in wild pathogenic viral populations in the UK.

Background

A causal association between high-risk human papillomaviruses (HPV) infection – particularly HPV-16 – and cervical cancer has been established. HPV-16 E5 is a minor oncoprotein comprising of 83 amino acids and in silico predictions suggest it comprises of 3 anchor-like α-helices (residues 8–30, 37–52 and 58–76): with only the first being sufficient to span a lipid bilayer (Figure 1). A region within the second helix (residues 41–54) may be the binding site for the pore sub-units of 16 KDa ATPase [1], though others claim it is located between residues 54–78 [2]. HPV-16 E5 is believed to act in the early stages of the oncogenic process [3-6] and is membrane-associated, occurring in the Golgi apparatus and endoplasmic reticulum [7].

HPV-16 E5 acts co-operatively with epidermal growth factor (EGF) to stimulate mitosis. Whilst E5 may, or may not, bind directly to the EGF-receptor (EGFr) [8,9], it was initially believed to impair acidification of endosomes via interaction with 16 KDa ATPase [10,11] and thereby promote recycling of EGFr to the cell-surface [10]. Others have suggested: that E5 perturbs EGFr trafficking from early to late endocytic structures rather than influencing acidification [12]; or, that E5 uses 16 KDa ATPase as a chaperone to enter the Golgi [2,13].
causing which in turn migrate to the nucleus to phosphorylate enzyme cascades through the MEK and MAP kinases, dict this pathway E2F and – which causes pocket-protein phosphorylation, release of p21 expression (a cyclin-dependant kinase inhibitor and which activates and assembly of activator protein-1 heterodimers from fos

Whatever the initial processes, HPV-16 E5 stimulates c-ras, causing c-raf to attach to plasma membranes, activating enzyme cascades through the MEK and MAP kinases, which in turn migrate to the nucleus to phosphorylate c-fos transcription factors [14-17]. Ultimately, this permits assembly of activator protein-1 heterodimers from c-fos and c-jun and stimulation of mitosis [18-20]. E5 can interdict this pathway via: (i) the induction of protein-kinase C which activates c-raf [21]; (ii) initiation of c-jun and c-fos and junB transcription [22,23]; and (iii), repression of p21 expression (a cyclin-dependant kinase inhibitor which causes pocket-protein phosphorylation, release of E2F and – via de novo synthesis of cyclins A, B and E – mitosis [23]: Figure 2).

We have previously described HPV-16 E5 variants which encode novel E5 protein sequences [24]. Here we conjectured that these natural E5 protein variants may have differing mitogenic properties and that the amino acids involved in this process might be discernable. This proposal was based upon evidence that certain HPV-16 E5 variants are more prevalent than others in wild viral populations in our locality. We detected marked differences in the ability of individual HPV-16 E5 variants to induce transcription in stably transfected long-term NIH-3T3 cell lines, changes in cell-cycle profiles and cell-growth. Some variants were more mitogenic than the reference isolate of HPV-16 E5: others which were poorly mitogenic as a result of either amino acid changes or, low transcriptional efficiencies. Interestingly, those HPV-16 E5 variants most frequently detected in our local population (RFLP pattern 2) – and most commonly associated with cervical lesions – were those which had the greatest mitogenic activity in vitro.

**Results**

**HPV E5 constructs**

HPV-16 E5 variants: Leu⁴⁴Val⁶⁵ (AJ244882); Thr³⁷Leu⁴⁴Val⁶⁵ (AJ44863); Thr⁶⁴(AJ244840) [24]; Tyr⁴⁴Leu⁴⁴Val⁶⁵, (AJ24481); the HPV-16 reference E5 sequence [25,26] and HPV-6b E5 were amplified and cloned into pDNA3.1Myc-His. For each HPV-16 E5 variant, a control construct, containing a 'AAA stop' codon (at codon position three) was also cloned into pDNA3.1Myc-His.

All constructs and 'stop' controls had the correct DNA sequences after cloning (data not shown). T7 'run-off' transcripts were prepared and translated in cell-free wheat-germ expression assays spiked with ³⁵S-labelled
cysteine (all have 4 cysteines). Autoradiographs of polyacrylamide gel electrophoresis (PAGE) gels revealed equivalent levels of in vitro translation for all HPV-16 variants, but no evidence of protein products from the equivalent 'stop' controls (Figure 3A), confirming the fidelity of TAA ('stop') codons. However, different HPV-16 E5 variants were transcribed at different levels in stably-transfected (G418-selected) NIH-3T3 cell-lines, with Tyr8Leu44Val65 being expressed at higher level than either Thr37Leu44Val65, or Leu44Val65, whilst the Thr64 variant and reference sequence were transcribed at low level (Figure 3B). To assist data interpretation, cell-lines for all 'stop' constructs were pooled prior to subsequent experiments.

Co-operation between HPV-16 E5 and EGF

HPV-16 E5 co-operates with EGF to stimulate ³H-thymidine incorporation into DNA of human keratinocytes and murine fibroblasts [10]. Here we selected to analyse E5-induced mitosis by cell-cycle profiles as this may provide more detailed information than levels of ³H-thymidine incorporation alone (e.g. Figure 4A). To confirm the validity of this approach we determined whether there was a synergistic relationship between the reference sequence of HPV-16 E5 and EGF. Such a relationship between the EGF and HPV-16 E5 reference sequence was demonstrable (e.g. Figure 4B), in agreement with a previous study using a ³H-thymidine readout [10].

E5 variants induce different cell-cycle profiles in the presence of EGF

Compared to the 'stop' control, cells transfected with HPV-6b E5 or the HPV-16 E5 Thr64 variant did not induce changes in G0G1-phase cell percentages (versus 'stop', both p > 0.05: Figure 5). All other HPV-16 E5 variants caused reductions of G0G1-phase (all p < 0.05), this effect being greatest for Leu44Val65 and the reference isolate (respectively, -16.2% & -15.5% c.f. 'stop'). Modest reductions in G0G1-phase were observed for the Tyr8Leu44Val65 (-6.1%)

Figure 3
Expression of E5 protein in vitro and cell line mRNA.
(A) Autoradiographs of PAGE gels containing in vitro wheat germ protein translation products of HPV-16 E5 variants (G) and 'stop' codon controls (S), demonstrating ³⁵S-labelled 9.1 kDa products in the former, but not the latter. +: positive (luciferase), and -: negative kit controls. X: 1 ng HPV-16 RNA; Y: 0.1 ng HPV-16 RNA. (B) Expression of E5 mRNA detected by RT-PCR in transfected cell-lines analysed in the presence (+) or absence of reverse transcriptase. B: blank.

Figure 4
Co-operative effects of HPV-16 E5 and EGF upon the cell-cycle progression. A: Typical example of cell cycle analysis. B: Left to right: 'stop' control (S-phase = 8.25%); 'stop' control plus epidermal growth factor (EGF: S-phase = 13%); the reference isolate of HPV-16 (16: S-phase = 13.9%) and 16 with EGF (S-phase 37.6%). Results expressed as the mean and standard error of the mean for at least three independent measurements.
and Thr37Leu44Val65 (-7.4%) variants. The Thr64 variant had a similar cell-cycle profile to the ‘stop’.

Cells containing HPV-6b E5 or the HPV-16 E5 Thr64 variant resembled the ‘stop’ in their S-phase profiles (both p > 0.05). Increases in S-phase were high for the reference isolate (+17.6% c.f. the ‘stop’) and for the Leu44Val65 variant (+12.2%), but lower for Tyr8Leu44Val65 (+9.4%) and for Thr37Leu44Val65 (+6.3%; all p < 0.05). There were also increases in G2/M-phase percentages for cells containing Leu44Val65 (+5.8%; p < 0.05) or Thr37Leu44Val65 (+2.8%; p > 0.05). Other E5 variants induced insignificant increases of G2/M-phase percentages (Thr64 +1.8%; HPV-6b E5, +1.6%; reference isolate, +0.6%; and, Tyr8Leu44Val65, +0.2%; all p > 0.05).

**Figure 5**

Effects of E5 variants assayed with EGF upon cell-cycle profiles. Results are expressed as the mean percentage (plus SEM) of cells in different stages of cell-cycling (G0/G1, S & G2/M) for each of HPV-16 E5 variant tested (solid bars), HPV-6b E5 (diagonal stripes), ‘stop’ constructs (open bars). Numbers of experiments: ‘stop’, n = 21; HPV-6b, n = 6; HPV-16, n = 9; Thr64, n = 9; Leu44Val65, n = 18; Thr37Leu44Val65, n = 6; and, Tyr8Leu44Val65, n = 11.

**E5 variants with increased G2/M-phase percentages exhibit increased cell-growth**

Static analyses of cell-cycle profiles can be difficult to interpret as the percentage values are inter-dependent variables. Thus, different cell populations could have identical cell-cycle profiles, but vastly dissimilar growth rates [27,28]. This problem was addressed by determining cell-growth at 24, 48 and 72 h in media containing EGF and minimal (2% v/v) serum supplement. Cells transfected with Leu44Val65 and Thr37/Leu44Val65 variants exhibited most growth (Figure 6: both p < 0.02 versus the ‘stop’ at 72 h), whilst the HPV-16 E5 reference isolate induced a smaller increase in cell number (p < 0.05 versus the ‘stop’ at 72 h). Cells containing the Tyr8Leu44Val65 and Thr64 variants, or HPV-6b E5 grew slowly (all, p > 0.05 versus the ‘stop’ at 72 h). Alternate expression of cell-growth as cell-doubling times gave equivalent results (e.g. for: Leu44Val65 mean doubling time = 56.6 h; Thr37Leu44Val65 = 49 h; and, Tyr8Leu44Val65 = 118 h).

**Tyr8 substitution of HPV-16 E5 is associated with high levels of p21 protein**

HPV-16 E5 can repress p21 transcription [29]. We thus determined levels of p21 and cyclin B1 proteins in cells containing the HPV-16 reference E5 sequence as well as a variant with a high-growth rate (Leu44Val65) and one with a low-growth rate (Tyr8Leu44Val65). Cells containing Tyr8Leu44Val65 maintained high levels of p21 protein throughout the time course, whereas p21 was much lower in cells containing the reference isolate and, near undetectable for those containing Leu44Val65 (Figure 7). There was also a delay before cyclin B1 could be detected in cells containing Tyr8Leu44Val65 as compared to those stably transfected with the other two E5 proteins. These effects were not artefactual as levels of protein loaded were similar as indicated by the β-actin controls.

**Discussion**

We demonstrate that the reference isolate of HPV-16 E5 can co-operate with EGF to reduce the percentage of cells in G0/G1-phase, increase those in S-phase and increase cell-growth. HPV-6b E5 exhibited similar though much less marked changes than the HPV-16 E5 reference isolate, in agreement with a previous study [10]. In this report we have examined HPV-16 E5 variant activity under controlled conditions. Indeed, all were transcriptionally expressed under the same (T7) promoter and all had a minimal Kozak sequence [30] inserted around the initial ATG codon to insure equivalent translational efficiency. We have used these constructs to significantly extended previous observations observations on the biologic activity of HPV-16 E5 by analysing: HPV-16 E5 transcription in NIH-3T3 cells; cell-cycle progression; and, cell growth.
All HPV-16 E5 variants were translated in a cell-free wheat germ expression system equivalently, however, differences in E5 transcription were detected between stably transfected NIH-3T3 variant cell-lines. The HPV-16 E5 reference sequence and the Thr64 variant were transcribed at much lower levels than the other variants. Analysis of cell-growth curves indicated that those with low levels of mRNA were also those which were slower-growing (HPV-16 reference and Thr64) and had lower percentages of cells in G2M phase. In contrast for those transcribed to similar levels in NIH-3T3 cells, the Leu44Val65 and Thr37Leu44Val65 variants exhibited high growth but, this was not the case for Tyr8Leu44Val65. These data suggest that whilst the addition of Thr37 to the Leu44Val65 backbone is neutral, addition of Tyr8 is detrimental to cell-growth.

All HPV-16 E5 constructs – aside from Thr64 variant – caused a fall in the percentage of cells in G0/G1-phase and an increase in S-phase, indicating that these variant E5 proteins stimulate passage through the G1/S cell-cycle checkpoint. Such an increase in the proportion of cells in S-phase may be advantageous to HPV-16, permitting it to increase the number of viral copies per cell prior to division.

The HPV-16 E5 Leu44Val65 and Thr37Leu44Val65 variants, had greatest percentages of cells in G2M-phase and in greatest cell-growth. This biological activity may help explain why these particular E5 (i.e. RFLP pattern 2) variants are most prevalent (~70%) amongst wild populations of HPV-16 in inner-city London and most strongly associated with the presence of cervical lesions [24]. In contrast, the Tyr8Leu44Val65 variant (which induced low cell growth) is an RFLP pattern 5 variant which is detected rarely amongst patients with lesions. Interestingly, the HPV-16 E5 RFLP pattern 2 HPV-16 E5 variants also co-segregate with nucleotide variation in the long control region that results in enhanced viral transcription via co-operation with the human POU transcription factor Brn3A [31]. The Leu44Val65 substitutions may act to improve the structural integrity of E5 protein as both are $\alpha$-helix stabilisers, whereas isoleucine (present at both sites in the reference isolate) is a helix destabiliser [32]. However, comparison of computer-predicted transmembrane regions [33] of the reference and Leu44Val65 variant did not reveal significant differences (data not shown). Another possibility is that the Iso→Val65 change may enhance the activity of two putative E5 functional domains: the voltage gating motif ($^{55}$Ser-x-x-Arg-x-x-x-x-Iso-$^{I_506}$-Phe-Val-x-x-Pro-x-x-Leu-x-x-His$^{77}$: [34]), present in the HPV-16 E5 reference isolate and all reported mammalian connexins; and, the proposed binding site for 16 kDa ATPase (aa 54–78: [2]). Conversely, another E5 variant with an adjacent change at position 64 (Thr64 variant) exhibited an impoverished biological activity, confounding E5-induced mitogenesis at the G0/G1 checkpoint.

At least three EGF-independent E5 pathways exist (Figure 1), most notable being the transcriptional repression of p21 by E5 directly [35] or, indirectly, via E5 induction of
c-jun [27,35]. The fact that cells containing the Tyr8Leu44Val65 variant had the highest levels of p21 protein implies that the serine usually present at residue 8 may play an essential role in p21 repression. As the reference isolate and the Leu44Val65 variant respectively exhibited an intermediate and low level of p21 expression it could also be inferred that residues 44 and 65 may also be involved in p21 repression.

Accumulation of high levels of p21 protein in cells containing the Tyr8Leu44Val65 variant is also likely to effect cell-growth by up-regulating apoptosis. Indirect evidence for this was observed in the cell-growth assays: at 24 h numbers of Tyr8Leu44Val65 containing cells had fallen to 67% of the seeding concentration (100%), in contrast those containing Leu44Val65 variant increased to 137% (data not shown). These differences were even more marked at 48 h: Tyr8Leu44Val65 cells were down to 54%, whereas cells containing Leu44Val65 had nearly doubled (190%).

We also observed a reciprocal association between the levels of p21 and cyclin B1, this has been reported by others in several cell-systems and may represent a direct inhibitory effect of p21 upon cyclin-B1 biosynthesis [36,37]. Unlike the Tyr8Leu44Val65 variant, insertion of a threonine (at position 64) into the Leu44Val65 backbone appeared to have no marked effect.

**Conclusion**

Using naturally-occurring amino acid sequence variants of HPV-16 E5 we have demonstrated that: (i) introduction of Thr64 into the reference E5 sequence abrogates mitogenic activity most probably through low levels of transcription; (ii) combined substitution of Leu44Val65 into the E5 reference backbone significantly enhances cell-cycle progression and cell-growth; (iii) addition of Thr57 to the Leu44Val65 variant had little effect upon mitogenic activity; and, (iv) inclusion of Tyr8 into the Leu44Val65 backbone severely inhibited E5 growth and E5 repression of p21 expression. These effects of HPV-16 E5 amino acid changes upon mitosis may – in part – help to explain why Leu44Val65 HPV-16 E5 variants are most prevalent in ‘wild’ viral populations in the UK. Thus we suggest amino acids 8 and 64 are critical for the mitogenic activity of HPV-16 E5.

**Methods**

**HPV samples**

HPV-16 E5 variants isolated from clinical samples: Ted (Leu44Val65, EMBL accession number AJ244882), 9785 (Thr27Leu44Val65, AJ44863) and Twp3 (Thr64, AI244840) [24] were studied. Permission for the collection of clinical specimens was provided by the Research Ethics Committee of St Thomas’ Hospital. In addition, E5 DNA from: HPV-16 containing CaSki cells (Tyr8Leu44Val65, AJ24481); the reference isolate of HPV-16 [25,26]; and, from the low cancer-risk virus HPV-6b were investigated.

**Construction of recombinant DNA expression vectors**

HPV-16 E5 genes were amplified in polymerase chain reactions (PCR) using 
1/th DNA polymerase in two separate reactions, so that E5 open reading frames (ORF) between nucleotides (nt) 3866 and 4077 (encoding E5 amino acids 6–76) were obtained. The first PCR utilised an upstream primer (GGA3836GGAGCTAGCCTACCTGCAAAATCCGTATA3865) which included an artificial Nhe-I cut site (underlined) and a minimal Kozak sequence [30] (3847ACCATGG3853) this motif was incorporated to promote equivalent translational efficiency for all constructs and introduces an artificial alanine residue at codon position two). The second PCR used a 5’ primer (3836GGAGCTAGCTCACATGGCAATACTTGATA3865) that also contained a ‘stop’ signal (underlined): both PCR products utilised the same downstream primer encoding an artificial BamHI site (3810TACGAGCTCTTATG TATAAAAAAGCCGTGCATG4078). E5 PCR products were ligated into the NheI and BamH1 sites of pcDNA3.1Myr-His (Invitrogen Ltd.). The E5 open reading frame (ORF) of HPV-6b E5 was also PCR amplified (using the upstream primer: 4103TACTATATGTGCTAGCCCACTAGGTGTCTAA4135 and downstream, 4364TACAAATATAAAAAACGGGGATCCCTAAATTTAGTATCGTAT4332) and cloned using the same strategy. Plasmids were transformed into E. Coli JM109 cells and selected by ampicillin resistance. Positive colonies were screened by PCR and then sequenced to confirm the identity of the DNA inserts.

**In vitro translation**

A cell-free wheat-germ expression assay (Promega Ltd.) was used to determine protein translation of T7 mRNA transcripts with individual reactions supplemented with 5 µl of 35S-labelled cysteine (1 Ci/l: Amersham International Ltd.). Radiolabelled cysteine was selected since all HPV-16 E5 variants contain 4 cysteine residues. Proteins were subjected to PAGE (below) and radioactivity detected by autoradiography.

**Preparation of stable NIH-3T3 cells expressing HPV E5 mRNA**

NIH-3T3 cells (ATCC Ltd.) were maintained in Dulbecco’s minimum essential medium supplemented with 40 mM L-glutamine, 2 × 10⁻⁶ U/l benzyl-penicillin, 2 g/l streptomycin sulphate (DMEM) and 10% (v/v) fetal calf serum (DMEM/FCS), in a humidified atmosphere of 5% (v/v) carbon dioxide in air. Cells were transfected with E5 containing plasmids using Lipofectin™ and grown in DMEM/FCS containing 1 g/l of G418 for 3 weeks (a dose cytotoxic for non-transfected NIH-3T3 cells within one week). Indi-
idual colonies of G418-selected cells were isolated and expanded in DMEM/FCS containing G418 to produce cell-lines for each variant. Individual cell-lines for each 'stop' construct were pooled. Variant cell-lines and the 'stop pool' were tested intermittently for mycoplasma infections: all were negative. Cell lines were tested for E5 mRNA expression using an adaptation of the method described by Biswas et al. [5]. Briefly reverse transcriptase (RT) reactions were primed using the HPV-16 E5 downstream primer (\texttt{4110TACAGGATCCTTATGTA ATTAAAGGCGTGCAT4078}) with Moloney murine leukemia virus reverse transcriptase then samples were subjected to a nested PCR using internal primers located within the E5 ORF [5].

**Cell-cycle analyses**

NIH-3T3 cells transfected with HPV-16 variants, HPV-16 'stop', or HPV-6b were seeded at 0.1 × 10^6 cells in 5 ml of DMEM/FCS (containing no G418) into 25 cm² flasks. Cells were serum-starved for 24 h in DMEM, media was then replaced with fresh DMEM with (or without) recombinant human EGF (20 μg/l: Boehringer-Mannheim Ltd.) and cells incubated for a further 24 h. Bromo-deoxyuridine (BrdUrd; 10 μM in DMEM) were added and cells washed twice by centrifugation through 10 ml of Dulbecco's phosphate buffered saline (PBS) for 5 min at 200 g at room temperature (rt) and then fixed with 2 ml of ice-cold aqueous 70% (v/v) ethanol. Fixative was removed and cells incubated in 1 ml of 0.1 M HCl containing 1 g/l pepsin for 12 min at 37 °C. Reactions were halted by centrifugation (as above) through, and re-suspension in, PBS. Murine monoclonal anti-BrdUrd IgG₁ heavy and kappa light chains (Becton-Dickenson Ltd: 250 μl per litre of PBS which contained 0.5% [v/v] Tween-20™ and 1% [v/v] FCS) was added for 1 h at rt, cells were washed with PBS and then incubated for 30 min at rt in the dark with fluoresceine-isothiocyanate (FITC) labelled Fab₂ fragments of rabbit anti-mouse immunoglobulin (Dako Ltd.) at rt. After a further wash in PBS cells were re-suspended in, and stained with, 1 ml of propidium iodide/RNAse solution (50 g propidium iodide and 200 g RNAse/l PBS) for 15 min at rt before analysis on a Becton-Dickenson flow cytometer (FACScalibur\textsuperscript{TM}). Data from 10,000 events (i.e. stained cells) were analysed (for a minimum of four times) for each reading after separation of single intact nuclei from debris and cell-clumps by gating on an FL2 area/width plot. Cells were then characterised on the basis of detection of green (FITC) and red (propidium iodide) fluorescence.

**Cell-growth**

Cells were grown in 2% (v/v) in DMEM containing 2% (v/v) fetal calf serum, supplemented with EGF (20 μg/l), after seeding at a density of 0.1 × 10^6 cells in 20 cm² Petri dishes. Cells were fed daily with fresh media containing EGF and cultures harvested at 24, 48 and 72 h by detachment from Petri dishes by exposure to Versene (5 ml for 2 min at 37 °C). One millilitre of DMEM/FCS was added to inactivate the trypsin then cells were pelleted by centrifugation (200 g for 15 min at rt). Cell pellets were re-suspended in DMEM/FCS and viable cell numbers determined immediately by trypan-blue exclusion staining [38].

**Western blots**

NIH-3T3 cells (0.1 × 10^6 cells in 5 ml of DMEM/FCS containing no G418) into 20 cm³ Petri dishes and left overnight. Cells were serum-starved for 24 h in DMEM, grown in DMEM supplemented with EGF (as above), then harvested over an 18 h period. Cells were lysed by suspension in RIPA buffer and cellular debris removed by centrifugation at 10,000 g for 30 sec at rt. Protein concentrations were determined using a commercial assay (BioRad Ltd.) and adjusted to enable 5 μg of total protein to be added to each well of a PAGE gel. Cellular proteins were subjected to PAGE under reducing conditions through a 4–12% Tris/glycine gradient gel (Novex Ltd.) and blotted onto Hybond-P™ membranes (Amersham International Ltd.). Each blot was next cut into strips containing the proteins of interest: cyclin B1 (60 kDa), β-actin (42 kDa) and p21 (21 kDa). Strips were blocked overnight at rt using 5% (w/v) dried milk powder (Marvel\textsuperscript{TM}, Premier Brands UK Ltd.) in Tris-buffered saline/Tween\textsuperscript{™} (20 mM Tris [hydroxymethyl]-amino methane; 0.2 M sodium chloride and 0.1% [v/v] Tween-20\textsuperscript{™}, pH 7.5: TBS-T).

Blot strips were washed three times with TBS-T then incubated for 1 h at rt with rabbit anti-β-actin (1/1000 dilution), mouse anti-p21 (2.5 mg/l) or, mouse anti-cyclin B1 (2 mg/l: Pharminogen Ltd.) antibodies. After two washes in TBS-T strips were immersed in the appropriate horse-radish peroxidase-labelled secondary antibody (sheep anti-mouse immunoglobulin or donkey anti-rabbit immunoglobulin: Amersham International Ltd. each at a dilution of 1/250) for 1 h at rt. Bound antibody was detected using an ECL-plus\textsuperscript{™} chemiluminescence kit and ECL Hyperfilm\textsuperscript{™} (Amersham International Ltd.).

**Statistical analyses**

Students’ t-tests were used to assist the interpretation of data.

**Abbreviations**

ATCC, American type culture collection; BrdUrd, Bromodeoxyuridine; DMEM, Dulbecco’s minimal essential medium; EGF, epidermal growth factor; EGFr, epidermal growth factor receptor; EMBL, European molecular biology laboratory; FACS, Fluorescence activated cell sorting; FCS, fetal calf serum; FITC, Fluoresceine isothiocyanate; HPV, human papillomavirus; KDa, Kilo Daltons; ORF,
Open reading frame; PAGE, Polyacrylamide gel electrophoresis; PBS, Dulbecco's phosphate buffered saline; PCR, Polymerase chain reaction; RIPA, Radio-immuno-precipitation assay; rt, Room temperature; RT, Reverse transcriptase.

rtTh, Recombinant thermostable Thermus thermophilus DNA polymerase; TBS, Tris buffered saline; TBS-T, TBS-Tween \(^{+}\); UK, United Kingdom.

Competing interests
The author(s) declare that they have no competing interests.

Authors' contributions
RN prepared samples, PCR amplifications and DNA sequencing. CM designed and perfected the PCRs and assisted in data analyses. BK oversaw the molecular biological approach to this project and assisted with data analyses. JC devised the research and assisted with the data analyses. JC directed the cell-cloning, cell-growth and cell-cycle analyses.

Acknowledgements
We wish to thank The Richard Dimbleby Cancer Fund and of Guy’s and St Thomas’ Hospitals Charity for financial support. We wish to thank Ms. R. Gilchrist for expert technical assistance and advice on the analyses of cell-cycling experiments.

References
1. Adam JL, Briggs MW, McCance DJ: A mutagenic analysis of the E5 protein of human papillomavirus type 16 reveals that E5 binding to the vacuolar H\(^{+}\)-ATPase is not sufficient for biological activity, using mammalian and yeast expression systems. Virology 2000, 272:315-325.
2. Rodriguez MI, Finbow ME, Alonso A: Binding of human papillomaviruses 16 E5 to the 16 kDa subunit c (proteolipid) of the vacuolar H\(^{+}\)-ATPase can be dissociated from the E5-mediated epidermal growth factor receptor overactivation. Oncogene 2000, 19:3723-3732.
3. Stoler MH, Rhodes CR, Whitebeck A, Wolinsky SM, Chow LT, Broker TR: Human papillomavirus type 16 and 18 gene expression in cervical neoplasias. Human Pathol 1992, 23:117-127.
4. Kell B, Jewers RJ, Cason J, Pakarian F, Kaye JN, Best JM: Detection of E5 oncoprotein in human papillomavirus type 16-positive cervical scrapes using antibodies raised to synthetic peptides. J Gen Virol 1994, 75:2451-2456.
5. Biswas C, Kell B, Munt C, Jewers RJ, Cason J, Muir P, Raju KS, Best JM: Detection of human papillomavirus type 16 early-gene transcription by reverse transcription-PCR is associated with abnormal cervical cytology. J Clin Microbiol 1997, 35:1560-1564.
6. Hsieh CH, Tsao YP, Wang CH, Han CP, Chang JL, Lee YF, Chen SL: Sequence variants and functional analysis of human papillomavirus type 16 E5 gene in clinical specimens. Arch Virol 2000, 145:2273-2284.
7. Conrad M, Bubb VJ, Schlegel R: The human papillomavirus type 6 and 16 E5 proteins are membrane-associated proteins which associate with the 16-kilodalton pore-forming protein. J Virol 1993, 67:6170-6178.
8. Conrad M, Goldstein D, Andersson T, Schlegel R: The E5 protein of HPV-6, but not HPV-16, associates efficiently with cellular growth factor receptors. Virology 1994, 200:796-800.
9. Hwang ES, Notzol T, DiMaio D: The HPV16 E5 protein: expression, detection, and stable complex formation with transmembrane proteins in COS cells. Virology 1995, 211:227-233.
31. Ndisang D, Faulkes DJ, Gascoyne D, Lee SA, Ripley BJ, Sindos M, Singer A, Budhram-Mahadeo V, Cason J, Latchman DS. Differential regulation of different human papilloma virus variants by the POU family transcription factor Brn-3a. Oncogene 2006, 25:51-60.

32. Lehninger AL: Biochemistry, the molecular basis of cell structure and function. Pub: Worth Inc, N.Y; 1975:130.

33. [http://pref.etos.hr/split/].

34. Ullman CG, Haris PI, Kell B, Cason J, Jewers RJ, Best JM, Emery VC, Perkins SJ. Hypothetical structure of the membrane-associated E5 oncoprotein of human papillomavirus type 16. Biochem Soc Transact 1994, 22:439S.

35. Tsao YP, Huang CH, Lin YK, Chen SL. Protein kinase C-and ras-dependent activation of c-jun gene by human papillomavirus type 11 E5a oncoprotein. Cancer Lett 1995, 95:201-205.

36. Choi YH, Zhang L, Lee WH, Park KY. Genistein-induced G2/M arrest is associated with the inhibition of cyclin B1 and the induction of p21 in human breast carcinoma cells. Int J Oncol 1998, 13:391-396.

37. McGrath-Morrow SA, Stahl J. Growth arrest in A549 cells during hyperoxic stress is associated with decreased cyclin B1 and increased p21(Waf1/Cip1/Sdi1) levels. Biochem Biophys Acta 2001, 1538:90-97.

38. Boyse EA, Old LJ, Chououmilkou L. Methods in Medical Research. Volume 10. Edited by: Eisen HN. Pub: Chicago Year Book Medical Publishers, Chicago; 1964:39.